G42, OceanX, G-Tech and the Indonesian Government to Collaborate to Advance Oceanic Research to Protect the Marine Environment
18.11.2022 20:10:00 EET | Business Wire | Press release
G42, the leading UAE-based AI and cloud computing company and global nonprofit ocean exploration organization OceanX, along with G-Tech Digital Asia (G-Tech), and the Government of the Republic of Indonesia via its Coordinating Ministry for Maritime Affairs and Investment (CMMAI) have announced the signing of a Letter of Intent to establish a collaboration to develop ocean research to help protect the marine environment.
In furtherance of this proposed collaboration, G42 intends to deploy G42 Cloud’s large-scale cloud infrastructure and services, remote sensing drone systems by Bayanat, a public listed company at ADX in which G42 owns a majority stake, and cutting-edge marine genomics applications by G42 Healthcare in the support of OceanX’s social welfare mission and its world-class marine research and media vessel the R/V OceanXplorer, to conduct advanced, in-depth analysis of the coastal and oceanic environments.
The Letter of Intent was signed by Mohammad Firman Hidayat, Acting Deputy Coordinating Minister for Maritime Resources, Peng Xiao, Group CEO of G42, Vincent Pieribone, Vice Chairman of OceanX and Michel Hamilton, CEO of G-Tech.
The collaboration will support the aims of the Indonesian government, led by CMMAI, to improve management of marine resources including biodiversity and conservation of ecosystems, through the use of new technology and methodologies and OceanX’s broader mission to explore the ocean and bring it back to the world through educational media.
The project recognizes the importance of detailed mapping of marine resources through advanced technologies in order to protect and preserve the ocean environment and the livelihoods of the communities that are reliant on it. G42 will support OceanX and CMMAI research with a focus on mapping fisheries and marine resources through data-driven e-DNA, socio-economic, and ecological characters in coastal-marine ecosystems. The proposed collaboration also includes training and knowledge transfer to build human capacity and supporting infrastructure for CMMAI.
In line with the UAE’s mandate to explore and leverage advanced technologies to spearhead the efforts towards environmental preservation, G42 is deploying its extensive portfolio of companies to develop new and better ways in which both public and private organizations can address some of the most pressing climate and environmental challenges.
Peng Xiao, Group CEO of G42 commented: “We are proud to be collaborating with CMMAI and OceanX on this project to develop a greater understanding of Indonesia’s marine environment. Better data is vital to developing a more holistic view of our oceans’ condition, and through our work with OceanX, we are looking to support the development of new, tailored solutions and technologies that will help local authorities to protect the marine environment, for the benefit of present and future generations.”
Dr. Prashanth Marpu, Director of Geospatial Centre Of Excellence and Climate Action Program at Bayanat said: “Oceans are highly complex environments, and monitoring and research can present many challenges to researchers and scientists working in this field. Bayanat is applying its expertise in real-time geospatial services and solutions and handling large-scale data to develop the tools that will allow the research community to leverage big data analysis of the maritime environment.”
About G42
G42 is a global leader in creating visionary artificial intelligence for a better tomorrow. Born in Abu Dhabi and operating across the world, G42 champions AI as a powerful force for good. Its people are constantly reimagining what technology can do, applying advanced thinking and innovation to accelerate progress and tackle society’s most pressing problems.
G42 is driving change in the region and beyond, joining forces with nations, corporations and individuals to create the infrastructure for tomorrow’s world. From molecular medicine to space travel and everything in between, G42 realizes exponential possibilities, today.
For further information visit www.g42.ai.
About OceanX
Oceanographic Research & Exploration Foundation (OceanX) is a mission to support scientists to explore the ocean and to bring it back to the world through captivating media. Uniting leading media, science, and philanthropy partners, OceanX utilizes next-gen technology, fearless science, compelling storytelling, and immersive experiences to educate, inspire, and connect the world with the ocean and build a global community deeply engaged with understanding, enjoying, and protecting our oceans. OceanX is an initiative of Dalio Philanthropies, which furthers the diverse philanthropic interests of Dalio family members.
For more information visit www.oceanx.org and follow OceanX on Facebook, Instagram, Twitter, TikTok and LinkedIn.
About Bayanat
Bayanat, an ADX listed public company with majority shareholding by G42, provides comprehensive world-class AI-powered geospatial solutions to a growing number of sectors such as Defense, Environment, Energy & Resources, Smart Cities and Transportation. It’s offering includes topographic, hydrographic and aeronautical products and charts, as well as spatial data surveying, analysis, management, modelling, visualization and cartography services. Bayanat’s solutions harness vast amounts of premium and unique data from a range of sources including Satellites, High Altitude Pseudo Satellites (HAPS) and Earth Observation powered by AI to drive geospatial intelligence (gIQ).
For more information, please visit: www.bayanat.ai
Twitter:
https://twitter.com/bayanat_ai
LinkedIn:
https://www.linkedin.com/company/bayanatg42/
Instagram:
https://www.instagram.com/bayanat.g42/
Facebook:
https://www.facebook.com/bayanat.g42
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005443/en/
Contact information
For media enquiries, please send an email to: g42@trailrunnerint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
